The investigational antisense oligonucleotide (ASO) therapy BIIB078 may have failed in amyotrophic lateral sclerosis (ALS) clinical trials because it wasn’t adequately reversing key disease processes in the brain and spinal […] The post New study may explain why ALS therapy BIIB078 didn’t work appeared first on ALS News Today.
